诚信认证：
工商注册信息已核实！
Abemaciclib (LY2835219)
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
| 货号 | CAS号 | 操作 |
|---|---|---|
| L124851-100mg | 1231930-82-7 | 询价 |
| L124851-10mg | 1231930-82-7 | 询价 |
| L124851-250mg | 1231930-82-7 | 询价 |
| L124851-25mg | 1231930-82-7 | 询价 |
| L124851-50mg | 1231930-82-7 | 询价 |
| L124851-5mg | 1231930-82-7 | 询价 |
属性
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
描述
| 产品介绍 | LY2835219对CDK4和CDK6的IC50分别为2 nM和10 nM。 |
| 生化机理 |
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. |
| 别名 | LY2835219；LY 2835219;LY-2835219；N-[5-[(4-乙基-1-哌嗪基)甲基]-2-吡啶基]-5-氟-4-[4-氟-2-甲基-1-异丙基-1H-苯并咪唑-6-基]-2-嘧啶胺甲烷磺酸盐;CDK4/6 dual inhibitor;LY 2835219;LY-2835219；N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine methanesulfonate (1:1) |
Abemaciclib (LY2835219)信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Abemaciclib (LY2835219)报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途